Budesonide Combination A Better Clinical Approach in Comparison to Cyclosporine in Treatment of Autoimmune Hepatitis

Rasmirekha Behera, Dept of Pharmacology I.M.S & SUM Hospital Bhubaneswar, India
2021 Journal of Medical Science And clinical Research  
Autoimmune hepatitis (AIH) is an uncommon though serious and potentially life-threatening disease which requires prompt recognition and treatment. In cases unresponsive to conventional treatment, achieving disease remission can be difficult. Keeping this in background in this study a comparision has been made between Budesonide combination with that of immunosuppressant i.e cyclosporine in treatment of Autoimmune Hepatitis. Methods: 30 AIH patients were included in this study. All patients were
more » ... divided into two groups i.e group A and B.15 patients Group A were treated with Budesonide 9mg/kg/day with Azathioprine 2mg/kg/day and 15 patients Group B were treated with Cyclosporine 3mg/kg/day. All the drugs were administered for 6 months. Result: All the patients with Budesonide and Azathioprine therapy were found to Antinuclear antibody negative after 6 months and more than 10 patients of Group A were found to have decrease in level of AST and ALT after 6 months. In patients with Cyclosporine therapy only 9 patients were found to be ANA negative after 6 months. Less than 10 patients were found to have decrease in levels of AST and ALT after 6 months in group B. Conclusion: Group A patients demonstrated a good biochemical response after 6 months of therapy in comparision to Group B patients. From this it is concluded that patients with Budesonide and Azathioprine therapy shows a significant improvement in AIH after 6 months in comparision to Cyclosporine therapy.
doi:10.18535/jmscr/v9i1.53 fatcat:jeeofquy45d4rfqvzwmohtmhpy